OMEICOS Therapeutics

company

About

OMEICOS Therapeutics is developing a novell molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation.

  • 11 - 50

Details

Last Funding Type
Series C
Last Funding Money Raised
€17M
Industries
Health Care,Medical,Therapeutics
Founded date
Jan 1, 2013
Number Of Employee
11 - 50
Operating Status
Active

OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activate an endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€17M
OMEICOS Therapeutics has raised a total of €17M in funding over 2 rounds. Their latest funding was raised on Nov 2, 2018 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 2, 2018 Series C €17M 1 SICAR Detail

Investors

Number of Lead Investors
Number of Investors
1
1
OMEICOS Therapeutics is funded by 1 investors. SICAR are the most recent investors.
Investor Name Lead Investor Funding Round
SICAR Yes Series C